This HTML5 document contains 110 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n6http://linked.opendata.cz/resource/drugbank/drug/DB00376/identifier/drugbank/
n9http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n24http://linked.opendata.cz/resource/AHFS/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00376/identifier/national-drug-code-directory/
n16http://linked.opendata.cz/resource/drugbank/company/
n27http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n14http://linked.opendata.cz/resource/drugbank/dosage/
n28http://linked.opendata.cz/resource/drugbank/mixture/
n4http://linked.opendata.cz/resource/drugbank/drug/DB00376/identifier/chemspider/
n25http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n20http://linked.opendata.cz/resource/drugbank/drug/DB00376/identifier/wikipedia/
n22http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00376/identifier/pharmgkb/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n19http://linked.opendata.cz/resource/drugbank/medicinal-product/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00376/identifier/kegg-compound/
owlhttp://www.w3.org/2002/07/owl#
n26http://linked.opendata.cz/ontology/mesh/
n5http://linked.opendata.cz/ontology/drugbank/
n17http://www.drugs.com/cdi/
n7http://linked.opendata.cz/resource/drugbank/property/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00376/identifier/pubchem-compound/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/resource/drugbank/drug/DB00376/identifier/pubchem-substance/
n29http://linked.opendata.cz/resource/atc/
n23http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00376
rdf:type
n5:Drug
n5:description
One of the centrally acting muscarinic antagonists used for treatment of parkinsonian disorders and drug-induced extrapyramidal movement disorders and as an antispasmodic. [PubChem]
n5:dosage
n14:271B63ED-363D-11E5-9242-09173F13E4C5 n14:271B63EE-363D-11E5-9242-09173F13E4C5 n14:271B63EF-363D-11E5-9242-09173F13E4C5 n14:271B63F0-363D-11E5-9242-09173F13E4C5
n5:group
approved
n5:halfLife
3.3-4.1 hours
n5:indication
Indicated for the treatment of parkinson's disease and extrapyramidal reactions caused by drugs.
n5:manufacturer
n16:271B63E0-363D-11E5-9242-09173F13E4C5 n16:271B63E1-363D-11E5-9242-09173F13E4C5 n16:271B63DE-363D-11E5-9242-09173F13E4C5 n16:271B63DF-363D-11E5-9242-09173F13E4C5 n16:271B63DD-363D-11E5-9242-09173F13E4C5 n16:271B63E6-363D-11E5-9242-09173F13E4C5 n16:271B63E4-363D-11E5-9242-09173F13E4C5 n16:271B63E5-363D-11E5-9242-09173F13E4C5 n16:271B63E2-363D-11E5-9242-09173F13E4C5 n16:271B63E3-363D-11E5-9242-09173F13E4C5
owl:sameAs
n22:DB00376 n25:DB00376
dcterms:title
Trihexyphenidyl
adms:identifier
n4:5371 n6:DB00376 n10:5572 n11:46507717 n12:61748-054-36 n13:C07171 n18:PA164747026 n20:Trihexyphenidyl
n5:mechanismOfAction
Trihexyphenidyl is a selective M1 muscarinic acetylcholine receptor antagonist. It is able to discriminate between the M1 (cortical or neuronal) and the peripheral muscarinic subtypes (cardiac and glandular). Trihexyphenidyl partially blocks cholinergic activity in the CNS, which is responsible for the symptoms of Parkinson's disease. It is also thought to increase the availability of dopamine, a brain chemical that is critical in the initiation and smooth control of voluntary muscle movement.
n5:packager
n16:271B63DC-363D-11E5-9242-09173F13E4C5 n16:271B63DA-363D-11E5-9242-09173F13E4C5 n16:271B63DB-363D-11E5-9242-09173F13E4C5 n16:271B63D4-363D-11E5-9242-09173F13E4C5 n16:271B63D5-363D-11E5-9242-09173F13E4C5 n16:271B63D2-363D-11E5-9242-09173F13E4C5 n16:271B63D3-363D-11E5-9242-09173F13E4C5 n16:271B63D8-363D-11E5-9242-09173F13E4C5 n16:271B63D9-363D-11E5-9242-09173F13E4C5 n16:271B63D6-363D-11E5-9242-09173F13E4C5 n16:271B63D7-363D-11E5-9242-09173F13E4C5 n16:271B63CC-363D-11E5-9242-09173F13E4C5 n16:271B63CD-363D-11E5-9242-09173F13E4C5 n16:271B63CA-363D-11E5-9242-09173F13E4C5 n16:271B63CB-363D-11E5-9242-09173F13E4C5 n16:271B63D0-363D-11E5-9242-09173F13E4C5 n16:271B63D1-363D-11E5-9242-09173F13E4C5 n16:271B63CE-363D-11E5-9242-09173F13E4C5 n16:271B63CF-363D-11E5-9242-09173F13E4C5 n16:271B63C5-363D-11E5-9242-09173F13E4C5 n16:271B63C8-363D-11E5-9242-09173F13E4C5 n16:271B63C9-363D-11E5-9242-09173F13E4C5 n16:271B63C6-363D-11E5-9242-09173F13E4C5 n16:271B63C7-363D-11E5-9242-09173F13E4C5
n5:synonym
Benzhexol Hydrochloride Trihexyphénidyle Trihexyphenidyl Apo-trihex (RS)-1-cyclohexyl-1-phenyl-3-(1-piperidyl)propan-1-ol Trihexyphenidylum Trihexifenidilo
n5:toxicity
Symptoms of overdose include mydriasis, dryness of mucous membranes, red face, atonic states of bowels and bladder, and hyperthermia in high doses. Central consequences are agitation, confusion, and hallucinations. An untreated overdose may be fatal, particular in children. Premortal signs are respiratory depression and cardiac arrest.
n23:hasAHFSCode
n24:12-08-04
n5:mixture
n28:271B63C3-363D-11E5-9242-09173F13E4C5 n28:271B63C4-363D-11E5-9242-09173F13E4C5 n28:271B63C2-363D-11E5-9242-09173F13E4C5
n5:salt
n26:hasConcept
n27:M0021972
foaf:page
n9:trihexyphen.htm n17:trihexyphenidyl.html
n5:IUPAC-Name
n7:271B63F5-363D-11E5-9242-09173F13E4C5
n5:InChI
n7:271B63FB-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n7:271B63FA-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n7:271B63F7-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n7:271B63F8-363D-11E5-9242-09173F13E4C5
n5:SMILES
n7:271B63F9-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n7:271B63F3-363D-11E5-9242-09173F13E4C5
n5:logP
n7:271B63F1-363D-11E5-9242-09173F13E4C5 n7:271B63F4-363D-11E5-9242-09173F13E4C5 n7:271B640C-363D-11E5-9242-09173F13E4C5
n5:logS
n7:271B63F2-363D-11E5-9242-09173F13E4C5
n23:hasATCCode
n29:N04AA01
n5:H-Bond-Acceptor-Count
n7:271B6401-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n7:271B6402-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n7:271B63FC-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n7:271B63FD-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n7:271B63FF-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n7:271B63FE-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n7:271B6400-363D-11E5-9242-09173F13E4C5
n5:absorption
Trihexyphenidyl is rapidly absorbed from the gastrointestinal tract.
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
144-11-6
n5:category
n5:containedIn
n19:271B63E9-363D-11E5-9242-09173F13E4C5 n19:271B63EA-363D-11E5-9242-09173F13E4C5 n19:271B63E7-363D-11E5-9242-09173F13E4C5 n19:271B63E8-363D-11E5-9242-09173F13E4C5 n19:271B63EB-363D-11E5-9242-09173F13E4C5 n19:271B63EC-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n7:271B6407-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n7:271B6409-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n7:271B640A-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n7:271B640B-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n7:271B6406-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n7:271B6405-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n7:271B6408-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n7:271B63F6-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n7:271B6403-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n7:271B6404-363D-11E5-9242-09173F13E4C5